Intravenous Iron: Indications, Dosing, and Monitoring
When to Use IV Iron
Intravenous iron should be used over oral iron for patients requiring rapid iron correction, those with insufficient response to oral iron (hemoglobin increase <1 g/dL or ferritin not reaching 30-50 ng/mL within 4-12 weeks), patients intolerant of oral iron due to gastrointestinal side effects, those with malabsorptive conditions, and pregnant individuals in the second and third trimesters with iron deficiency anemia. 1
Specific Clinical Indications
The 2025 Lancet Haematology guidelines provide clear criteria for IV iron use 1:
Adults (non-pregnant):
- Oral iron failure after 4-12 weeks of treatment
- Gastrointestinal intolerance to oral iron
- Malabsorptive conditions (celiac disease, inflammatory bowel disease, post-bariatric surgery)
- Need for rapid correction of iron deficiency
- Chronic inflammatory conditions (chronic kidney disease, heart failure, inflammatory bowel disease, cancer) 2
Pregnant individuals:
- Second and third trimester iron deficiency anemia (preferred over oral iron for maternal outcomes) 1
- Optimal timing: <34 weeks gestation with ≥6 weeks latency before delivery 3
Dosing Regimens
Total dose infusion (single administration) is preferred over multiple-dose treatment 1. Modern formulations allow administration of full therapeutic doses in 15-60 minutes 4, 5.
Specific Dosing by Formulation
- Ferric carboxymaltose: 15 mg/kg body weight, up to 1000 mg maximum per dose 6
- Iron isomaltoside 1000: 20 mg/kg body weight with no ceiling dose, administered over 1 hour 6
- Ferumoxytol: Maximum 510 mg per administration (US only, limited to CKD) 6
- Iron sucrose: 200-300 mg over 2 hours is safe; 400-500 mg doses have higher adverse event rates 7
For pregnancy: Doses ≥800 mg with ≥6-8 weeks latency before delivery provide optimal hemoglobin improvement (2.6-3.1 g/dL increase) 3
For chronic kidney disease: High-dose low-frequency administration is recommended for most adults; low-dose high-frequency may be appropriate for children and adults on in-center hemodialysis 8
Pre-Medication and Infusion Management
Routine pre-medication is NOT recommended 1, 4. This is a critical point that contradicts older practices.
Exceptions for Pre-medication
Consider pre-medication or slower infusion rates only for 1:
- History of previous infusion reactions to IV iron (consider alternative formulation first)
- Multiple severe drug allergies
- Inflammatory arthritis
Key Safety Points
- No test dose required for modern formulations 4, 6
- Anaphylaxis is exceedingly rare (<1:200,000 administrations) 4
- Most reactions are complement activation-related pseudo-allergy (CARPA/Fishbane reactions), not true anaphylaxis 4, 5
- Critical pitfall: Inappropriate intervention with vasopressors and H1 blockers for minor CARPA reactions converts them into hemodynamically significant events 5
Monitoring Procedures
Post-Infusion Assessment
Reassess treatment response no sooner than 4 weeks after infusion 1. This allows adequate time for iron incorporation and erythropoiesis.
Laboratory Monitoring
Baseline assessment:
- Serum ferritin
- Transferrin saturation (TSAT)
- Hemoglobin
- Consider red blood cell markers if available (percentage hypochromic red blood cells, reticulocyte hemoglobin content) 8
Response criteria at 4-12 weeks:
- Hemoglobin increase ≥1 g/dL
- Ferritin reaching 30-50 ng/mL 1
Treatment-Emergent Hypophosphatemia
Monitor phosphate levels, particularly with ferric carboxymaltose and ferric derisomaltose, as these formulations can cause hypophosphatemia 4, 5. This is a newly recognized side effect requiring clinical awareness.
Long-Term Management
Develop long-term monitoring and management plans for patients requiring ongoing IV iron 1. This includes:
- Identifying and treating underlying causes of iron deficiency
- Scheduled reassessment intervals
- Phosphate monitoring protocols
- Documentation of infusion reactions for future reference
Common Pitfalls to Avoid
- Do not use vasopressors for minor CARPA reactions - these resolve spontaneously 5
- Do not give routine pre-medication - increases unnecessary interventions 1, 4
- Do not assess response before 4 weeks - premature testing leads to inappropriate management 1
- Do not use enteric-coated or slow-release oral iron as alternative - these are ineffective 1
- Do not administer iron sucrose doses >300 mg over 2 hours - higher rates of adverse events 7